US 11,739,151 B2
Anti-PD-L1/anti-CD47 bispecific antibody
Jiawang Liu, Beijing (CN); Yaping Yang, Beijing (CN); Nanmeng Song, Beijing (CN); and Maengsup Kim, Beijing (CN)
Assigned to Beijing Hanmi Pharmaceutical Co., Ltd., Beijing (CN)
Appl. No. 16/769,108
Filed by Beijing Hanmi Pharmaceutical Co., Ltd., Beijing (CN)
PCT Filed Dec. 1, 2018, PCT No. PCT/CN2018/118800
§ 371(c)(1), (2) Date Jun. 2, 2020,
PCT Pub. No. WO2019/109876, PCT Pub. Date Jun. 13, 2019.
Claims priority of application No. 201711261880.8 (CN), filed on Dec. 4, 2017.
Prior Publication US 2021/0230277 A1, Jul. 29, 2021
Int. Cl. C07K 16/28 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2827 (2013.01) [C07K 16/468 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/55 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01)] 18 Claims
 
1. A bispecific antibody in the form of a heterodimer consisting of a first antibody, which comprises a first Fc chain and a first antigen-binding functional region that can specifically bind to human PD-L1; and a second antibody which comprises a second Fc chain and a second antigen-binding functional region that can specifically bind to human CD47;
wherein the first antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO.: 2, a light chain constant region comprising the amino acid sequence of SEQ ID NO.: 4, a heavy chain variable region comprising the amino acid sequence of SEQ ID NO.: 6 and a heavy chain constant region comprising the amino acid sequence of SEQ ID NO.: 8; and
wherein the second antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO.: 10, a light chain constant region comprising the amino acid sequence of SEQ ID NO.: 4, a heavy chain variable region comprising the amino acid sequence of SEQ ID NO.: 12 and a heavy chain constant region comprising the amino acid sequence of SEQ ID NO.: 14.